The 5-Gene-Multiplex 1% AF cfDNA in Plasma product from SensID is a highly specialized and critical tool for liquid biopsy assays, primarily used in diagnostic and research applications. This product is designed to target five key mutations across essential genes: AKT1, BRAF, KRAS, PIK3CA, and ERBB2, mutations that are commonly linked to a range of cancers including lung, breast, colorectal, and melanoma. These mutations play an important role in cancer progression and are crucial for making informed therapeutic decisions.

The 5-Gene-Multiplex 1% AF cfDNA in Plasma contains a 1% allelic frequency (AF) of the targeted mutations. It serves as a positive control standard for techniques like digital PCR and next-generation sequencing (NGS). This tool is especially useful in validating and developing sequencing protocols, PCR methods, and assessing detection limits, which are crucial for achieving accurate and reliable results.

The specific mutations included in this product are:

• AKT1 (p.E17K),
• BRAF (p.V600E),
• KRAS (multiple variants),
• PIK3CA (p.E545K, p.H1047R),
• ERBB2 (p.Y772_A775dup).

These mutations are essential for targeted therapies. For example, BRAF mutations like p.V600E are treated with drugs such as vemurafenib, while KRAS mutations are addressed with therapies like cetuximab. Similarly, mutations in PIK3CA and AKT1 direct personalized treatments.

The 5-Gene-Multiplex 1% AF cfDNA in Plasma product is indispensable for advancing cancer diagnostics, especially in the rapidly evolving field of liquid biopsy testing. By providing a reliable and accurate benchmark, it helps facilitate the development of more precise and personalized cancer treatments, ensuring that assays used for liquid biopsy can detect genetic mutations with confidence and clarity.